Stockwinners Market Radar for March 28, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:18 EDT Cathie Wood's ARK Investment bought 114K shares of Twist Bioscience today

19:50 EDT Pluri trading halted, news pending

18:27 EDT Walgreens Boots Alliance CEO: We're focused on improving front end of the store - In an interview on CNBC's Mad Money, Tim Wentworth said Walgreens is "knee deep" in an analysis of the business and how it's going to move forward. "A year from now you're going to find a company that is more focused," he noted. It launched nearly 40 new private labels this quarter, and over 80% of online orders were delivered within an hour, he added. He is "super confident" of the revival of the front end of the store. Shrink is not equal across all stores, and the company is working "really hard" to reduce it, he said.

18:01 EDT Descartes Systems acquires OCR for roughly $90M - Descartes Systems Group announced that it has acquired OCR Services, a provider of global trade compliance solutions and content. "The OCR team brings a wealth of domain expertise in global trade compliance to Descartes, including experience leveraging artificial intelligence (AI) in the content management process," said Andrew Roszko, Chief Commercial Officer at Descartes. "By adding OCR's solutions and content to our Global Logistics Network, we see an opportunity to bring new functionality and enhanced content to our customers and partners around the world. With our combined solutions and team, we also see an opportunity to further penetrate markets in Europe and Asia." "We continue to invest in solutions and content to help our customers manage the complete lifecycle of shipments in what is an increasingly dynamic global regulatory environment," said Edward J. Ryan, Descartes' CEO. "OCR complements our Global Trade Intelligence business, particularly our Visual Compliance and MK Data investments. We're thrilled to welcome the OCR employees, customers and partners into the Descartes family." OCR is headquartered in Rockville, Maryland. Descartes acquired OCR for approximately $90M, satisfied from cash on hand.

17:28 EDT Marathon Oil exec Wagner sells 34,094 common shares - In a regulatory filing, Marathon Oil executive VP Patrick Wagner disclosed the sale of 34,094 common shares of the company on March 27 at a price of $27.6469 per share.

17:06 EDT Tricon's private acquisition by Blackstone Real Estate approved by shareholders - Tricon Residential shareholders voted to approve the statutory plan of arrangement pursuant to which Blackstone Real Estate will acquire all of the outstanding common shares of Tricon for $11.25 per common share in cash. Of the votes cast, a total of 208,391,666 shares were voted in favor of approving the arrangement, approximately 99.3% of shareholder votes. Tricon intends to seek a final order from the Ontario Superior Court of Justice to approve the arrangement on April 5. Subject to the satisfaction or waiver of all of the conditions, the transaction is expected to be completed in Q2. Following completion, the common shares will be delisted from the NYSE and the TSX and the company will apply to cease to be a reporting issuer under applicable Canadian securities laws and will deregister the common shares under the U.S. Securities Exchange Act of 1934.

16:52 EDT Oxford Industries down 5% at $106.38 after Q4 miss, below-consensus guide

16:50 EDT Torrid jumps 26% to $6.13 after Q4 earnings beat and guidance

16:46 EDT Advance Auto Parts director buys $401K in common stock - In a regulatory filing, Advance Auto Parts disclosed that its director Brent Windom bought 4.7K shares of common stock on March 27th in a total transaction size of $401K. Shares of Advance Auto Parts are up 1.1% afterhours at $86.00.

16:34 EDT Applied Therapeutics: FDA extends review period for NDA for govorestat - Applied Therapeutics announced that the U.S. FDA has extended the review period for the New Drug Application for govorestat (AT-007) for the treatment of Classic Galactosemia by three months. The FDA has set a new Prescription Drug User Fee Act target action date of November 28. The FDA notified Applied Therapeutics that it required additional time to review supplemental analyses of previously submitted data that had been provided by Applied in response to the FDA's routine information requests and determined that the additional information constitutes a Major Amendment to the NDA. In February 2024, the company announced that the FDA accepted and granted Priority Review to the NDA. Govorestat was previously granted Pediatric Rare Disease designation, and will qualify for a Priority Review Voucher upon approval.

16:25 EDT Keysight Technologies SVP Narayanan sells 4,300 common shares - In a regulatory filing, Keysight Technologies senior VP Kailash Narayanan disclosed the sale of 4,300 common shares of the company on March 26 at a price of $152.88 per share.

16:18 EDT Hilton Grand Vacations appoints Dusty Tonkin as Chief Sales & Marketing Officer - Hilton Grand Vacations announced that Dan Mathewes has been promoted to president, along with the continuation of his role as CFO. In addition, the company has named Dusty Tonkin as its new EVP, Chief Sales & Marketing Officer. Tonkin most recently served as the Chief Sales & Marketing Officer for Bluegreen Vacations. Prior to his time at Bluegreen Vacations, he was the executive VP of sales & marketing at Wyndham Destinations.

16:15 EDT Bristol Myers says KRYSTAL-12 trial met primary endpoint in PFS - Bristol Myers Squibb announced that the pivotal Phase 3 KRYSTAL-12 study, evaluating KRAZATI as a monotherapy in patients with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRASG12C mutation, met the primary endpoint of progression-free survival and the key secondary endpoint of overall response rate as assessed by Blinded Independent Central Review at final analysis for these endpoints. The study remains ongoing to assess the additional key secondary endpoint of overall survival. Results of the confirmatory trial showed that KRAZATI demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to standard-of-care chemotherapy as a second-line or later treatment for these patients. KRAZATI had no new safety signals and the safety data was consistent with the known safety profile. "Today's news is an important reinforcement of the power of a targeted therapy for patients with locally advanced or metastatic KRASG12C-mutated lung cancer. FDA approval of KRAZATI in the U.S. has allowed us to provide a new treatment option for these patients, and topline results of the KRYSTAL-12 confirmatory study will build greater trust in the medical and patient community," said Abderrahim Oukessou, M.D., vice president, global program lead, KRAZATI, Bristol Myers Squibb. "We are encouraged by the results from KRYSTAL-12 and look forward to helping more patients with KRASG12C-mutated lung cancer." The company will complete a full evaluation of the available data and looks forward to sharing the results with the scientific community at an upcoming medical conference as well as discussing the results with health authorities.

16:12 EDT Utz Brands approves annual dividend increase to 23.6c per share from 22.8c - The increase is effective as of today, and the Utz Board of Directors has declared a regular quarterly cash dividend of approximately $0.059 per share on the Company's Class A Common Stock. Payment is expected to be made by the Company on May 2, 2024, to stockholders of record at the close of business on April 15, 2024.

16:10 EDT Veritex announces $50M stock buyback program - Veritex announced that its board of directors authorized a stock buyback program pursuant to which the company is authorized to purchase up to $50M shares of the company's outstanding common stock. The stock buyback program has an expiration date of March 31, 2025 and may be suspended, terminated, amended or modified by the board at any time without prior notice at the board's discretion. The stock buyback program is expected to be funded using the company's cash on hand and cash from operations of Veritex Community Bank. Repurchases under the stock buyback program may be made, from time to time, in amounts and at prices the company deems appropriate. The stock buyback program does not obligate the company to purchase any shares of its common stock. Repurchases by the company under the stock buyback program will be subject to general market and economic conditions, applicable legal and regulatory requirements and other considerations. In addition, Veritex announces completion of a restructuring of it's available-for-sale debt security portfolio in March by selling approximately $120.1M of lower-yielding AFS debt securities, at amortized cost, with a yield of 3.11% at a $6.5M pre-tax loss. Approximately $115.9M of the proceeds were reinvested in higher yielding AFS securities with a 6.24% yield.

16:04 EDT EverCommerce names Ellora Sengupta as new CIO - EverCommerce announced today two new members joining its executive leadership team. Ellora Sengupta joins EverCommerce as CIO. In this newly-created role that will support the Company's transformation and optimization efforts, Ms. Sengupta will provide executive leadership and oversight in enhancing and maintaining the company's corporate systems, infrastructure and security, enterprise technology, data infrastructure & analytics. EverCommerce has promoted Kayla O'Rourke to the position of Chief People Officer following the departure of Shane Driggers. Ms. O'Rourke joined EverCommerce in 2022 as Senior Vice President North America People and Talent Acquisition.

15:01 EDT General Dynamics Information Technology awarded $922M contract - General Dynamics Information Technology, a business unit of General Dynamics, announced that it was awarded a $922M contract to modernize the U.S. Central Command's enterprise IT infrastructure. The new contract, awarded in February by the General Services Administration, has a one-year base period and five option years. Under this contract, GDIT will operationalize enterprise data through artificial intelligence/machine learning technologies to improve decision-making, transition CENTCOM to a new cloud environment, and enhance the effectiveness and efficiency of its networks. The company will also leverage its zero trust capabilities to bolster CENTCOM's cyber defenses and protect against future cyber threats.

13:04 EDT Evolv up after NYC announces new technology to detect firearms for subways - New York City Mayor Eric Adams and New York City Police Department Commissioner Edward Caban announced efforts being taken to make the Metropolitan Transit Authority's subway system safer by investing in new technology to detect firearms, as well as invest in more clinicians that will help those suffering from severe mental illness in the nation's largest subway system. Strength in shares of Evolv, which makes weapon detection systems, is being attributed to the announcement. In afternoon trading, Evolv shares are up 25c, or 7%, to $3.88. Reference Link

13:00 EDT NYC Mayor announces rollout of new weapon detection system for subways - Strength in shares of Evolv has been attributed to the announcement. Reference Link

12:14 EDT A SPAC I Acquisition Corp trading resumes

12:00 EDT Boston Omaha falls -7.6% - Boston Omaha is down -7.6%, or -$1.25 to $15.22.

12:00 EDT AMC Entertainment falls -14.9% - AMC Entertainment is down -14.9%, or -65c to $3.69.

12:00 EDT REX American Resources rises 28.9% - REX American Resources is up 28.9%, or $12.71 to $56.63.

11:52 EDT StoneBridge Acquisition Corp trading resumes

11:42 EDT StoneBridge Acquisition Corp trading halted, volatility trading pause

11:29 EDT Keyarch Acquisition Corp trading resumes

11:24 EDT Keyarch Acquisition Corp trading halted, volatility trading pause

10:47 EDT LAMF Global Ventures I Corp trading halted, volatility trading pause

10:08 EDT Mayfair Gold receives shareholder meeting requisition - Mayfair Gold has received a shareholder meeting requisition notice pursuant to section 167 of the Business Corporations Act dated March 27, 2024 from MWCGOF SPV III LP, a fund controlled by Muddy Waters Capital. The Requisitioning Shareholder purports to hold in excess of five percent of the issued common shares of the Company. The shareholder meeting is being requisitioned to consider: a special resolution to remove all of the directors of the Company; if the Director Removal Resolution is passed, an ordinary resolution fixing the number of directors at four; if the Director Removal Resolution is not passed, an ordinary resolution fixing the number of directors at eight or such lesser number equal to the number of the directors of the Company then in office plus four; and electing four director nominees of the Requisitioning Shareholder. The Company is reviewing the Requisition, with the assistance of its professional advisors, and will respond appropriately in due course. In the meantime, there is no need for shareholders to take any action. Mayfair's President and CEO, Patrick Evans, commented: "The Company is grateful for the many expressions of support it has received from shareholders. It is unfortunate that Muddy Waters has chosen to escalate its demands over-and-above those set out in its news release of only a week ago, rather than engage in constructive dialogue with the Company."

10:06 EDT BuzzFeed, The Independent sign long-term license, strategic partnership - Independent Digital News and Media Ltd and BuzzFeed, Inc. announced they have entered into a multi-year license and strategic partnership. The companies will combine their publishing, data, and ad-tech platforms to allow commercial partners to buy across their sites, with combined on-site audiences that together reach half of all British consumers. As part of the deal, BuzzFeed, Inc.'s UK staff - both commercial and editorial - will move over to The Independent, with BuzzFeed, Inc. providing its global content, tech, and support to The Independent.

10:04 EDT Acadia Healthcare acquires three treatment centers in North Carolina - Acadia Healthcare Company has recently completed the acquisitions of three comprehensive treatment centers in North Carolina. Two of the locations, rebranded as Raleigh Comprehensive Treatment Center and Greenville Comprehensive Treatment Center, are located in Raleigh, North Carolina, and Greenville, North Carolina, respectively. The third acquired location, rebranded as Hillsborough Comprehensive Treatment Center, in Hillsborough, North Carolina, serves residents in communities from Durham to Burlington. With these additions, Acadia now operates 10 CTC locations in North Carolina and 160 locations in 32 states across the country.

10:02 EDT Weave announces integration with Athenahealth - Weave announced an integration with Athenahealth, a provider of network-enabled software and services for medical groups and health systems nationwide. This integration allows healthcare providers to better manage their business through automation and optimization of tasks by unlocking certain Weave features.

10:00 EDT Home Depot suspending share repurchases until debt returns to 2x EBITDA - Home Depot, on its conference call discussing its agreement to acquire SRS Distribution, said it is suspending share repurchases until it gets back to its targeted 2.0 times adjusted debt to EBITDA.

10:00 EDT Chemours falls -13.4% - Chemours is down -13.4%, or -$3.87 to $25.02.

10:00 EDT Ouster rises 13.6% - Ouster is up 13.6%, or 91c to $7.61.

10:00 EDT Andretti Acquisition rises 25.4% - Andretti Acquisition is up 25.4%, or $2.62 to $12.92.

09:56 EDT WeTrade Group Inc trading resumes

09:47 EDT Andretti Acquisition Corp trading resumes

09:47 EDT REX American Resources rises 20.4% - REX American Resources is up 20.4%, or $8.96 to $52.88.

09:47 EDT Franklin Covey falls -10.8% - Franklin Covey is down -10.8%, or -$4.14 to $34.16.

09:47 EDT GCT Semiconductor falls -19.6% - GCT Semiconductor is down -19.6%, or -$8.62 to $35.38.

09:42 EDT Andretti Acquisition Corp trading halted, volatility trading pause

09:37 EDT MITER Brands completes acquisition of PGT Innovations - PGT Innovations announced that MIWD Holding Company completed the acquisition of PGTI. The transaction was announced on January 17, 2024, and received approval of PGTI's stockholders on March 18, 2024. In accordance with the definitive merger agreement, PGTI stockholders will receive $42.00 in cash for each share of PGTI common stock. With the completion of the acquisition, PGTI's common stock has ceased trading and will no longer be listed on the NYSE. The transaction was financed in part by an equity investment from an affiliate of Koch Equity Development, the principal investment and acquisition arm of Koch Industries, that is a current investor in MITER Brands.

09:34 EDT Binah Capital Group Inc trading halted, volatility trading pause

09:31 EDT FibroBiologics files patent application covering fibroblast-based technology - FibroBiologics announced the filing of a patent application with the United States Patent Office covering the use of FibroBiologics' fibroblast cell-based technology for the potential treatment of Lupus.

09:22 EDT Omega Therapeutics sees cash runway into 1Q25 - As of December 31, 2023, the Company had cash, cash equivalents and marketable securities totaling $73.4 million, which is expected to fund operations into Q1 2025.

09:21 EDT Kerrisdale says short MicroStrategy, long Bitcoin - Kerrisdale Capital tweeted: "GM. We're short $MSTR and long bitcoin. Report avail at http://kerr.co/mstr. Crypto trades often get carried away and $MSTR is no exception. The BTC price implied in $MSTR shares is now over $177k, an unjustifiable 2.6x the spot price of BTC." Reference Link

09:11 EDT PubMatic reinvests 2023 profits to bolster engineering, sales teams - PubMatic announced a significant reinvestment of profits to bolster its engineering and sales teams. This strategic move aims to propel the company's growth trajectory by enhancing technological innovation, strengthening client relationships, and expanding market reach. PubMatic recently reported record revenue of $267M in 2023, continuing the company's long track record of strong profitability, high margins, zero debt, and significant free cash flow. This differentiated financial profile sets the foundation for continued investment in the business to accelerate revenue growth and drive increased customer and shareholder value. The company plans to onboard over 150 incremental employees over the course of 2024, a 16% increase year-over-year, bringing the total company headcount to approximately 1,100 by the end of the year. The reinvestment plan includes a substantial increase in hiring across engineering and sales divisions, with a focus on the highest impact areas of the business, including: Activate and Supply Path Optimization: expanding buyer-focused sales and customer success teams by 50% in 2024 to increase penetration with agency holding companies, independent agencies and brands; Connect and Post-Cookie Solutions: growing the team building addressability solutions such as Connect, Identity Hub, and Privacy Sandbox solutions, to ensure clients' businesses are safeguarded against ongoing signal loss; Emerging Revenue Streams: hiring additional sales and customer success team members focused on solutions such as our enterprise grade OpenWrap software and our commerce media solution, Convert; and Performance Advertising: increasing the number of product managers and machine learning engineers focused on building and scaling ROI and outcomes-based advertising solutions that rival the walled gardens. The impact of the expanded engineering organization will be further amplified by the company's ongoing efficiency investments. The company anticipates a 15-20% increase in engineering productivity in 2024 driven by the use of generative AI at multiple points in the software development and release process.

09:09 EDT Backblaze gets StateRAMP Progressing Snapshot, TX-RAMP Provisional authorization - Backblaze has earned inclusion in StateRAMP's Progressing Snapshot and the TX-RAMP Provisional programs. These programs standardize security requirements by assessing solutions that serve state and local government and education institutions, empowering public institutions to level up their data security with safeguards that meet verified security standards.

09:08 EDT LPL Financial: Windward Wealth joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Erick Simonds, Eugene Sninski, II, and Lisa Sninski have joined LPL Financial's broker-dealer, RIA and custodial platforms. They reported serving approximately $250 million in advisory, brokerage and retirement plan assets and join LPL from Wells Fargo Advisors. Based in Brick, N.J., Erick and Eugene have worked together as a team for approximately 17 years, with Lisa joining three years ago. All three have deep ties to the community and have grown their practice by cultivating meaningful relationships with local businesses, charities and schools. They use a diversified, risk-based wealth management process to help pre-retirees establish wealth, transition to retirement and plan for their legacy.

09:06 EDT Syla Technologies' SYLA Solar announces issuance of Series 1 unsecured bonds - SYLA Technologies announced its subsidiary, SYLA Solar has successfully raised 50 million yen in bank guaranteed private placement bonds provided by Aichi Bank, Ltd. This fundraising initiative aims to fortify SYLA Solar's business operations and facilitate further growth. Specifically, the funds will be allocated towards advancing investment in research and development efforts to promote the development of new technologies and products. This includes the expansion of its production facilities to streamline and reinforce the mass production system and improve its capacity to supply products to the markets. Additionally, SYLA Solar intends to improve customer satisfaction and expand its market share by broadening sales channels and enhancing customer service. Through these endeavors alongside the recent business alliance with LIVE THE CREATIVE, SYLA Solar is poised not only to strengthen its operational capabilities but also to make further contributions to the promotion of sustainable energy.

09:05 EDT Beyond Meat unveils new, expanded line of Beyond Crumbles - Beyond Meat announced a newly renovated and expanded line of Beyond Crumbles rolling out now in the freezer aisle at grocery stores across the U.S. "We continue to innovate across our product lines to deliver delicious taste and health benefits alike. For consumers who love the taste and versatility of beef, but want to reduce saturated fat and cholesterol in their diet, Beyond Crumbles offer a convenient, healthy protein for the center of the plate. Beyond Crumbles' strong nutritional profile, coupled with its simple and clean ingredient list, earned the product certification by the American Heart Association's Heart-Check program and the American Diabetes Association's Better Choices for Life program," said Beyond Meat Founder and CEO Ethan Brown.

09:04 EDT Bio-Techne and Nikon partner for spatial biology services - Bio-Techne announced that Lunaphore, part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments to expand access to spatial biology services with the COMET platform for US-based biotech, pharma, and academic customers. Lunaphore's COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities, which performs protein detection with standard, non-conjugated antibodies. The Nikon BioImaging Lab is a research and innovation hub recently established by Nikon in the Greater Boston area, with the mission of providing contract imaging solutions, AI-enhanced analysis and bioassay development services to foster research and drug discovery. Together, Lunaphore and the Nikon BioImaging Lab will be able to leverage their complementary expertise in microscopy-based imaging and analysis to bring COMET technology and spatial biology to the greater scientific community.

09:04 EDT Bowlero promotes Zac Sulma to chief sales officer - Bowlero announced the promotion of Zac Sulma as chief sales officer. Sulma will be responsible for enhancing future sales initiatives. Sulma will report directly to Thomas Shannon, Bowlero's founder, chairman, and CEO.

09:03 EDT Senmiao Technology regains Nasdaq compliance - Senmiao Technology announced that it has received a letter from the Nasdaq Listing Qualifications Staff, dated March 26, 2024, notifying the company that it has regained compliance with the minimum bid price requirement under the Listing Rules of The Nasdaq Stock Market. The letter noted that as a result of the closing bid price of the company's common stock having been at $1.00 per share or greater for 20 consecutive business days, from February 27, 2024 to March 25, 2024, the fcompany has regained compliance with Listing Rule 5550(a)(2), and the matter is now closed.

09:01 EDT Cognizant extends strategic agreement with LexisNexis Legal & Professional - Cognizant has announced a multi-year extension of its strategic agreement with LexisNexis Legal & Professional, a global provider of information and analytics. Through this renewed agreement, Cognizant will continue providing cloud and digital engineering services, helping accelerate feature releases and streamline operational efficiency through automation and cost optimization of LexisNexis' next-gen legal research solution, Lexis+. LexisNexis extended its relationship with Cognizant due to the company's proven track record as a long-trusted provider.

08:50 EDT Solitario discovers new gold zone on Golden Crest project - Solitario Resources reports that it has discovered another high-grade gold zone on its Golden Crest project, named Sleeping Beauty. Recently received assay results from reconnaissance rock sampling of outcrop, sub-crop and float from the 2023 field season yielded gold values as high as 39.6, 24.6 and 16.6 grams per tonne gold. Sleeping Beauty is situated on a topographic plateau underlain by the same favorable limestone found at the high-grade Geyer gold zone, which is located about 500 meters to the south. The two zones are separated by a shallow valley, where mineralization is considerably weaker at surface and rock outcrops are absent. Although the Sleeping Beauty zone has an apparent east-west orientation, the overall trend of mineralization over a larger scale area is thought to be generally in a northeast-southwest direction. Approximately 135 samples were collected and assayed from the Sleeping Beauty topographic plateau area. Twenty-eight of these samples assayed greater than 1.0 gpt gold, with 65 samples greater than 0.2 gpt gold. Within the 1600-meter-long trend, there are five clusters of higher-grade gold. The highest-grade cluster measures 170 by 260 meters and is open in all directions. The average grade of all 14 grab samples collected in this high-grade cluster is 7.12 gpt gold.Chris Herald, President and CEO of Solitario, stated: "In the late summer of 2023 we began to focus on a large area north of Geyser, as the north side of Geyser was open to expansion. This area, that we now call Sleeping Beauty, has developed into one of the largest target areas yet discovered at Golden Crest. Although sampling is still in the early days at Sleeping Beauty, we believe that it will develop into a major high-grade target area with the additional work we have planned for 2024. Importantly, we anticipate reporting our final assay results from the 2023 field season over the next several weeks."

08:48 EDT Camber Energy announces issuance of patent by USPTO - Camber Energy announced that on March 26, 2024, the U.S. Patent and Trademark Office issued U.S. patent11,942,776 entitled "Electric Transmission Line Ground Fault Prevention Systems Using Dual Parameter Monitoring With High Sensitivity Relay Devices in Parallel With Low Sensitivity Relay Devices". This new patent is part of a portfolio of intellectual property that has been incorporated into Broken Conductor Protection technologies: designed to detect a broken conductor anywhere on a transmission circuit and de-energize the line within half of a second before it touches the ground or a grounded structure; which do not interfere with existing protection; work on all transmission circuits in conjunction with existing equipment; are more reliable than other solutions because they leverage the physics of a transmission circuit; and designed to prevent broken conductors from starting fires and/or injuring persons. The technology is designed to be an integral component within a much-needed, worldwide grid hardening and stability initiative by electric utilities to improve resiliency and reliability of existing infrastructure. The new patent was issued to Viking Protection Systems, LLC, a majority-owned subsidiary of Camber's wholly-owned subsidiary, Viking Energy Group, Inc.

08:46 EDT Bridgeline Digital releases Zeus update with concept, image search - Bridgeline Digital announced that Smart Search by HawkSearch, featuring AI powered concept and image search with Generative AI (GenAI) capabilities, is now available to the general public. Smart Search leverages the latest advancements in AI, including large language models and vector databases, to empower online shopping search functionality. "I've spent most of my life in AI research and the last 24 months have seen more progress in AI than the last 24 years," said Ari Kahn, CEO of Bridgeline. "AI has changed expectations for online shoppers and Smart Search powers Bridgeline's customers to bound past their competitors with a more intuitive shopping experience that converts online visitors to online buyers. This release affirms our dedication to fostering our customers' success in the increasingly competitive online marketplace."

08:45 EDT ReShape Lifesciences receives notice of allowance for additional U.S. patent - ReShape Lifesciences announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office, USPTO, for patent application 18/370,819, entitled, "Intragastric Device." When issued, the patent will cover claims for an intragastric balloon system, comprising a capsule configured to be swallowable by a patient and to degrade in a gastric environment, with a balloon compacted and contained within the capsule, the balloon including an outer and inner surface, an interior cavity, a fill valve and release valve wherein the fill valve and release valves are separate valves, among other claim features. Once issued, the patent will provide protection into at least January 2031, without accounting for a potential Patent Term Extension.

08:43 EDT Assure Holdings closes sale of certain assets to MPOWERHealth - Assure Holdings closed the sale of certain assets of its IONM business to MPOWERHealth on March 26, 2024. The sale includes proceeds of up to $4.5 million, of which $2.32 million was paid in cash at the initial closing and up to an additional $2.18 million to be paid in relation to a potential earnout payment tied to case volume from the acquired assets during the 12-month period following the initial closing. The asset sale includes most of the Company's healthcare facility contracts and clinical equipment, and a majority of the Company's employees. The Company retains certain of its assets, including but not limited to, its accounts receivable and its employees in the revenue cycle management team.

08:42 EDT Dyadic International appoints Lucy as Chairman of board, changes to the board - Dyadic International announced that Michael Tarnok is stepping down as Chairman of Dyadic's board of directors and that current member of the Board Patrick Lucy has been appointed to succeed him, in each case, effective immediately. Tarnok will continue to serve as a director through the end of his current term, which will end at the Company's annual meeting in June 2025, at which time he expects to retire. In addition, Dr. Barry Buckland announced that he is retiring and therefore will not stand for re-election at the Company's annual meeting in June 2024. The Board has decided not to fill the vacancy due to Dr. Buckland's retirement which will result in a reduction of the size of the Board from seven to six members. Finally, Joseph Hazelton has been appointed Chief Operating Officer, effective immediately, and will oversee the day-to-day operations of the Company. Lucy joined the Board in January 2021 and serves on the company's Science and Technology Committee.

08:40 EDT CISO Global enters into exclusive agreement with Fortegra - CISO Global and The Fortegra Group have entered into an exclusive agreement to provide product protection plans for CISO Global cybersecurity clients via Fortegra's P&C Group subsidiaries. "Partnering with CISO Global marks a forward-thinking step in both cybersecurity and insurance," said Cooper Wallach, VP of Specialty Products and Programs at Fortegra. "It's a fusion of our extensive specialty insurance experience and the latest technology, offering unmatched protection and showcasing our collective commitment to safeguarding digital futures."

08:39 EDT Transcode Therapeutics announces appointment of Vlock as CMO - TransCode Therapeutics announced that Daniel Vlock, M.D., has been appointed as the company's Chief Medical Officer, CMO. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University.

08:37 EDT Bannix Acquisition, GBT partner to bring VisionWave to market - Bannix Acquisition together with GBT Technologies announced that the Company and VisionWave Technologies Inc., which is partially owned by GBT have executed a binding Business Combination Agreement with the goal of bringing a groundbreaking imaging technology called "VisionWave" to market. This technology platform, backed by a portfolio of patents, leverages the power of radio waves and machine learning to create a new frontier in computer vision. The companies said, "VisionWave has promise to revolutionize imaging and detection, particularly in military/combat and geological survey applications. Using radio waves, the goal of the system, which is under development, is to: Analyze reflections to create detailed 2D and 3D images of stationary and moving objects, including living beings, above and below ground. Offer 360 degrees coverage through AI-driven radio wave analysis, providing unparalleled situational awareness. Integrate seamlessly with existing radar systems, enhancing their capabilities with advanced features. While the path to commercialization requires additional research, development, and strategic partnerships for successful market introduction, both Bannix and VisionWave are confident in the transformative potential of VisionWave. This innovative technology has the potential to redefine imaging and detection across various industries, from military applications to security and medical diagnostics."

08:34 EDT PTC Therapeutics submits MAA for sepiapterin in PKU to EMA - PTC Therapeutics submitted the sepiapterin MAA to the European Medicines Agency, or EMA. The MAA submission is for the treatment of pediatric and adult patients with Phenylketonuria, including the full spectrum of disease subtypes. Phenylketonuria, or PKU, is a rare, inherited metabolic disease, which affects the brain. The sepiapterin MAA includes the results of the phase 3 APHENITY trial in which sepiapterin had a statistically significant and clinically meaningful reduction in blood phenylalanine levels in pediatric and adult PKU patients. PTC expects to submit the sepiapterin NDA to the FDA no later than the third quarter of 2024. Submissions in 2024 are planned in a number of additional key countries where PTC has existing rare disease commercial infrastructure including Brazil and Japan.

08:29 EDT Biodexa says early trials of MTX110 show promise in extending life expectancy - Biodexa Pharmaceuticals is developing MTX110 for the treatment of Diffuse Midline Glioma in pediatric patients and for Recurrent Glioblastoma in adults; two aggressive brain cancers with universally poor prognoses. The company says early trials of MTX110 in both cancers show promise in extending survival rates beyond those reported in previously published studies. DMG tumors are highly aggressive grade IV tumors that exhibit a propensity to infiltrate the surrounding tissues. Commonly found throughout the brainstem, these tumors pose significant challenges in treatment. The median overall survival rate for individuals - typically children diagnosed with diffuse midline glioma is less than one year - generally ranges from eight to 11 months. A small percentage, approximately 10%, manage to survive for at least two years following diagnosis. Glioblastoma is the most prevalent malignant primary tumor of the central nervous system in adult patients and is known for its aggressive nature and tendency to invade surrounding tissues. Although GBM is rare, it carries a high fatality rate, with an incidence of 3.44 per 100,000 individuals and a median overall survival of only eight months, regardless of treatment. The five-year survival rate stands at a mere 7.2%. Recurrence poses a significant challenge for adult patients with GBM, and the prognosis remains bleak. Tumor recurrence, typically occurring within seven months from the initial diagnosis, is the primary cause of mortality. Both cancers have a high mortality rate and a high unmet need. Biodexa is hoping to meet these needs as it further develops MTX110. The main chemotherapy agent of MTX110, panobinostat, was originally used to treat multiple myeloma and received FDA approval in 2015. The company is currently reworking the chemotherapy agent by changing its delivery method and leveraging Convection Enhanced Delivery technology. Researchers discovered that the original formulation of panobinostat was capable of blocking enzymes involved in cancer cell growth, exhibiting high potency against brain stem tumor cells in vitro and in vivo. However, the original oral tablet form is both insoluble and incapable of crossing the blood-brain barrier at therapeutic levels - making it an ineffective treatment method for brain cancers. The distinctive feature of MTX110 is that it combines a water-soluble form of panobinostat with a CED device that delivers the drug directly to the brain tumor through a surgically implanted catheter and refillable pump. Biodexa says the drug achieves high drug concentrations within the tumor while limiting systemic exposure. The proof-of-concept phase 1 clinical trial of MTX110 took place at the University of California San Francisco with patients battling DMG. The trial produced promising results with a median overall survival of 26 months, compared to a historical overall survival rate of 10 months. Similarly, a phase 1 trial involving newly diagnosed DMG patients at Columbia University Irving Medical Center also had encouraging outcomes, with MTX110 treatment increasing median overall survival to 16 months from a historical overall survival rate of 10 months. The findings from this study will be presented at the 21st International Symposium on Pediatric Neuro-Oncology, and the company may potentially continue developing the drug in this indication in a phase 2 study. Biodexa reports that the ongoing MAGIC-G1 phase 1 trial in recurrent GBM patients at Duke Cancer Institute and Baptist MD Anderson Cancer Center is currently showing considerable progress with completion of recruitment for cohort A of the study. The first patient survived for 12 months, and three patients currently remain in the study. The expected topline results for progression-free survival from cohort A will be available in Q2 of 2024. The retrospective analysis of 299 patients with similar recurrent GBM disease showed a median overall survival of only 6.5 months after the recurrence of GBM cancer.

08:26 EDT Tenon Medical appoints Kristine Jacques to board of directors - Tenon Medical announced that Kristine Jacques has been appointed as an independent member of the Company's Board of Directors on March 25, 2024, effective immediately. Following this appointment, Tenon Medical's Board of Directors consists of seven members, including four independent directors. Most recently, Ms. Jacques was Vice President & GM, Interventional Pain Therapies of Vivex Biologics.

08:23 EDT N2OFF granted patent approval in South Africa - N2OFF announces that one of Save Foods Ltd.'s patents has been granted in South Africa. This achievement emphasizes the Company's ongoing commitment to global food safety and sustainability while expanding its geographical distribution. The newly granted patent, "Sterilization Compositions and Methods for Use Thereof", refers to kits and methods for controlling pathogen load within or on the surface of edible plant matter.

08:22 EDT Emergent BioSolutions continues to broaden access of NARCAN nasal spray - Emergent BioSolutions remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN Nasal Spray to help save lives in opioid overdose emergencies. One year after Emergent obtained the historic OTC U.S. FDA approval in March 2023 and seven months since retail launch in August 2023, the availability of NARCAN Nasal Spray in pharmacies, grocery stores and online retailers has helped more people gain access to this life-saving product. Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN Nasal Spray, reducing stigma and further improving access for all Americans. "We're living in a time when one person dies approximately every six minutes from an accidental opioid overdose - prevention and response efforts require an all-hands on deck approach toward lessening this devastating public health crisis," said Joseph Papa, president and CEO of Emergent. "In my first month leading Emergent, and alongside our dedicated colleagues, we continue to advance our mission to protect the public from threats such as the opioid epidemic and am proud of our efforts to help save lives."

08:20 EDT Microchip expands Serial SRAM product line - To address a common customer need for bigger and faster SRAM, Microchip Technology has expanded its Serial SRAM product line to include larger densities of up to 4 Mb and increased Serial Peripheral Interface/Serial Quad I/O Interface speed to 143 MHz. The 2 Mb and 4 Mb devices are designed to provide a lower-cost alternative to traditional parallel SRAM products and include optional battery backup switchover circuitry in the SRAM memory to retain data on power loss.

08:19 EDT HarborOne Bancorp increases quarterly cash dividend 6.7% to 8c per share - HarborOne Bancorp announced that its board of directors has declared a quarterly cash dividend of 8c per share, which represents an increase of 6.7%, compared to its most recent dividend paid on January 18. The dividend will be paid on April 24 to all shareholders of record as of the close of business on April 10.

08:18 EDT Gorilla announces further expansion in the Thailand market - Gorilla Technology Group announced its further expansion in the Thailand market, tackling its burgeoning data center needs by introducing a comprehensive suite of full-stack offerings aimed at revolutionizing security convergence for these facilities. This strategic expansion marks a significant milestone for both Gorilla and the evolving technological landscape in Thailand. Data centers are the cornerstone of digital infrastructure and essential for various sectors by storing critical information. Gorilla, leveraging its recent success in creating Egypt's first AirGap Network, plans to enhance the security of Thailand's data centers with its Security Convergence portfolio. Utilizing its proprietary technology and collaborations with industry leaders, the company seeks to set a new benchmark in security for Thailand's data center landscape, thereby protecting both digital assets and physical infrastructure.

08:16 EDT Worksport announces receipt of solar panels required to begin production - Worksport announces the arrival of a large quantity of custom solar panels, which are required to begin production of the highly anticipated SOLIS Solar Tonneau Cover at the Company's New York State manufacturing facility. This milestone marks a significant step forward, allowing the Company to begin initial production of the SOLIS Solar Tonneau Cover. "We are incredibly excited about the progress of the SOLIS Solar Cover and the upcoming launch of the COR Battery System," said Steven Rossi, CEO of Worksport. "The arrival of the solar panels at our New York State facility is not just a milestone for us, but a testament to our team's dedication and hard work. We are eager to bring these innovative products to the market and make a positive impact on the environment and the automotive industry."

08:16 EDT GCM Grosvenor expands credit team with two hires - GCM Grosvenor announced the addition of Brandon Cahill and Scott Ingles to its established credit team. Cahill and Ingles' expertise and experience further bolster GCM Grosvenor's extensive credit capabilities, enhancing the firm's ability to provide innovative investment solutions to its clients. Brandon Cahill, joining as a Managing Director, brings a wealth of knowledge and a proven track record in credit investing to the firm. Most recently, Cahill spent nearly twenty years at BlueMountain Capital Management as Co-Head of the firm's global CLO business. Scott Ingles, joining as a Principal, brings nearly ten years of experience in credit management and risk assessment. Before joining GCM Grosvenor, Ingles held senior positions at The Carlyle Group and PointState Capital, where he managed credit portfolios across various sectors.

08:15 EDT Keysight looks to acquire Spirent Communications for 199 pence per share - Keysight Technologies announced its intention to acquire the entire issued and to be issued share capital of Spirent Communications for a cash consideration of 199 pence per Spirent share which values Spirent at approximately GBP1,158M or $1,.463B, on a fully diluted basis. Spirent shareholders will also be entitled to receive a special dividend of 2.5 pence per Spirent share, in lieu of any final dividend for the year ended 31 December Spirent's board of directors intend to unanimously recommend the Offer which is conditional on, among other things, the approval of the requisite majority of Spirent Shareholders at the Court Meeting and the Spirent General Meeting, as well as regulatory approval as laid out in the Offer announcement. Keysight views Spirent's business as highly attractive and aligned with Keysight's long-term software-centric solutions strategy. Keysight believes there is strategic synergy between the two businesses, and that the parties' respective complementary products will help customers address their complex engineering challenges. Keysight and Spirent are both focused on enabling secular technology megatrends across multiple end-markets, including communications, aerospace and defense, automotive, and enterprise sectors. With Spirent's offerings, Keysight expects to address new serviceable available market opportunities of up to $1.5B.

08:13 EDT Enphase Energy launches IQ8P microinverters in Thailand, the Philippines - Enphase Energy has started shipping IQ8P Microinverters, with peak output AC power of 480 W, for residential and commercial applications in Thailand and the Philippines to support newer high-powered solar modules.

08:12 EDT Compass Pathways co-founders depart from board, David Norton named interim chair - Compass Pathways announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina Malievskaia have resigned their seats on the company's board of directors, effective March 29, 2024. David Norton, lead independent director on the Compass board of directors, will become interim chair. Compass is running a global search for a permanent board chair, focused on recruiting a leader with a strong background in the biotechnology sector and broad strategic experience across the product lifecycle.

08:10 EDT 4D Molecular announce update on regulatory interactions, development for 4D-710 - 4D Molecular Therapeutic announced an update on its regulatory interactions and development path for 4D-710, an aerosolized genetic medicine for the treatment of CF lung disease. Given high-level cystic fibrosis transmembrane conductance regulator transgene expression in all lung airway biopsies disclosed to date, dose exploration continues with the evaluation of lower doses in the 4D-710 Phase 1/2 AEROW clinical trial in pwCF dosed at 5E14 vg and 2.5E14 vg; nine pwCF total have been dosed to date. Phase 2 Expansion Cohort dose selection is expected in Q2 2024 based on all clinical and lung biopsy data; the Company anticipates enrolling a total of six to nine pwCF in the Phase 2 Expansion Cohort. The Company submitted an AEROW trial amendment to the Cystic Fibrosis Therapeutics Development Network as follows: 1) to enroll pwCF with lower baseline percent predicted forced expiratory volume in 1 second to assess ppFEV1 response to 4D-710, and 2) to add a second lung biopsy procedure at a longer-term timepoint to study long term durability of 4D-710 CFTR transgene expression and optimal timing for redosing. In addition, the Company recently had discussions with the U.S. Food and Drug Administration and European Medicines Agency, regarding the registrational path for 4D-710 for treatment of CF lung disease in pwCF who are ineligible for or cannot tolerate approved CF modulator therapies. With regards to a full product approval in this patient population, the Company anticipates a Phase 3 randomized, controlled pivotal study enrolling approximately 60-80 pwCF with low baseline ppFEV1. Given the high unmet need in this CF population, an accelerated approval path may be feasible. The Company intends to have discussions with the FDA and EMA on an accelerated approval pathway, in parallel with Phase 3 planning, following additional AEROW clinical and lung biomarker data in pwCF with low baseline ppFEV1.

08:08 EDT MariaDB plc confirms receipt of proposal from Progress Software - The board of MariaDB plc (MRDB) confirmed that on March 26, it received an unsolicited non-binding indicative proposal from Progress Software (PRGS) to acquire the entire issued and to be issued share capital of the company. Progress publicly announced such offer on March 26. The board of MariaDB is reviewing and taking advice regarding the possible offer. The possible offer may or may not lead to an offer being made for the entire share capital of the company. There can be no certainty that any offer will be made. In accordance with Rule 2.6 of the Irish Takeover Rules, Progress is required, no later than 5:00 pm on May 7, being the 42nd day following the progress announcement, to either announce a firm intention to make an offer for the company in accordance with Rule 2.7 of the Irish Takeover Rules; or announce that it does not intend to make an offer for the company, in which case the announcement will be treated as a statement to which Rule 2.8 of the Irish Takeover Rules applies. This deadline will only be extended with the consent of the Irish Takeover Panel in accordance with Rule 2.6 of the Takeover Rules, at the request of the company.

08:06 EDT Imunon sees cash runway into 4Q24 - The Company ended 2023 with $15.7 million in cash, investments and accrued interest receivable. Along with future planned sales of the Company's remaining $1.3 million of New Jersey NOLs, the Company believes it has sufficient capital resources to fund its operations into the fourth quarter of 2024.

08:05 EDT NRx Pharmaceuticals announces 1-for-10 reverse stock split - NRx Pharmaceuticals announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:30 p.m. Eastern Time on Monday, April 1. The company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "NRXP" and will begin trading on a split-adjusted basis when the market opens on Tuesday, April 2. The new CUSIP number for the company's common stock following the reverse stock split will be 629444209.

08:03 EDT Stifel Financial reported February 2024 operating data - Total client assets: $458M; fee-based client assets: $172M. Ronald Kruszewski, Chairman and Chief Executive Officer, said, "In February, total client assets under management climbed to a record $458 billion, including a record $172 billion in fee-based assets. This represents a three percent increase from the prior month, driven by strong equity markets and financial advisor recruiting. Client money market and insured products increased 1% from January, despite modest seasonal cash sorting. While the environment for investment banking continues to improve, delays in deal closings remain a headwind for the business."

08:03 EDT Cocrystal Pharma sees cash runway beyond next 12 months - "All our programs target high-value unmet indications with novel, broad-spectrum, best-in-class antiviral candidates whose design and development uses our proprietary structure-based drug discovery platform technology," said James Martin, CFO and co-CEO. "I'm pleased to report that under our cost-efficient business model, we believe our cash position is sufficient to fund current operations including planned clinical studies beyond the next 12 months."

07:58 EDT Ceapro receives final court approval for merger with Aeterna Zentaris - Aeterna Zentaris and Ceapro announced that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction. The parties anticipate completing the Transaction in the second quarter of 2024, subject to obtaining all required approvals and satisfying all required conditions.

07:42 EDT ARway announces multiple SaaS developer sign-ups for AR platform - ARway.ai announced multiple new SaaS developer sign-ups for its augmented reality experience platform providing AR indoor navigation. ARway is delighted to welcome La Casa de Juana, a pioneering real estate platform based in Chile, to its growing network of innovative collaborators. With a strong presence in the Chilean market, La Casa de Juana specializes in offering comprehensive online services for evaluating and booking rental property tours. By signing up for ARway's developer plan, La Casa de Juana aims to prototype and introduce augmented reality real estate tours, leveraging ARway's technology. This initiative will allow clients to enjoy immersive property viewings, enhancing their decision-making process with a blend of virtual and real-world experiences. Navigine, a global provider of hardware-based indoor navigation and wayfinding software, headquartered in New York and Berlin, has chosen to incorporate ARway's augmented reality technology into its expansive tech stack. Navigine's expertise in utilizing WiFi and Bluetooth technologies, alongside its blue dot technology, offers indoor navigation experiences. Navigine specializes in indoor navigation through hardware and beacons, covering over 3,000 unique facilities.

07:36 EDT Hudbay Minerals provides annual reserve, resource update, outlook - Hudbay Minerals released its annual mineral reserve and resource update and issued new three-year production guidance. "Our updated mineral reserve estimates and three-year production outlook demonstrate Hudbay's high-quality operating platform with annual production of more than 150,000 tonnes of copper and 270,000 ounces of gold from three long-life mines located in tier-one mining friendly jurisdictions in the Americas," said Peter Kukielski, Hudbay's President and Chief Executive Officer. "We saw strong reserve conversion in Peru after successful geotechnical work confirmed the addition of another mining phase at Constancia, extending the mine life to 2041, and we continued to progress drill permitting activities for the high-potential exploration satellites in Peru. Manitoba exploration efforts are focused on advancing the largest geophysical and drilling program in our history in Snow Lake to test the newly acquired land claims for another anchor deposit and extend the mine life well beyond 2038. Our Copper Mountain mine has a robust copper production profile over its 21-year mine life as reflected in the recent technical report. We already have a resilient operating platform delivering stable copper production and complementary gold production, and we expect to continue to add to our robust production outlook by leveraging our proven track record of delivering value through exploration and development as we advance our quality pipeline of growth assets."

07:33 EDT Perspective Therapeutics sees cash runway into 2026 - Cash and cash equivalents as of December 31, 2023, was $9.2 million as compared to $21.0 million on December 31, 2022. During the first quarter of 2024, Perspective raised aggregate gross proceeds of $20.8 million in a January 2024 private placement, $69.0 million in a January 2024 public offering, and $87.4 million in a March 2024 private placement before deducting underwriting fees, placement agent fees, and other expenses. We believe that our cash and cash equivalents as of December 31, 2023 and the cash we raised through the January 2024 private placement and public offering and the March 2024 private placement will be sufficient to fund our operations and capital investments into 2026.

07:26 EDT Aldebaran Resources reports results for drill holes at Altar Copper-Gold project - Aldebaran Resources reports results for five drill holes of the 2023/2024 field campaign at the Altar copper-gold project in San Juan, Argentina. The holes reported herein were all substantial step-outs to the north or south of known mineralization. The holes were designed to test the edges of known mineralization and expand the mineralized footprint within the large, conductive MT geophysical anomaly at the Altar project. All holes hit mineralization and successfully extended the mineralized footprint of the deposit. Highlights: ALD-24-235: 362.50 m of 0.34% CuEq from 3.90 m depth Including 78.00 m of 0.54% CuEq from 25.00 m depth; 357.80 m of 0.27% CuEq from 424.20 m depth including 110.00 m of 0.41% CuEq from 428.00 m depth; 410.50 m of 0.36% CuEq from 811.00 m depth Including 266.50 m of 0.45% CuEq from 955.00 m depth Including 182.50 m of 0.52% CuEq from 1,039.00 m depth; Hole ended in this mineralization. ALD-24-236: 1,133.70 m of 0.23% CuEq from 213.00 m depth. ALD-24-237: 129.50 of 0.20% CuEq from 95.50 m depth. ALD-24-238: 1,159.50 m of 0.24% CuEq from 42.00 m depth Including 53.85 m of 0.46% CuEq from 274.00 m depth, Including 91.50 m of 0.47% CuEq from 1,110.00 m depth. ALD-24-239: 77.10 m of 0.19% CuEq from 250.00 m depth; Adds mineralization to an area that was defined as waste in 2021 resource estimate; 353.00 m of 0.46% CuEq from 696.00 m depth Including 233.00 m of 0.59% CuEq from 816.00 m depth, Including 122.00 m of 0.65% CuEq from 927.00 m depth; Hole ended in mineralization. Mineralization hosted in rhyolite, which historically at Altar has been a poor host rock and only mineralized when it's close to a mineralized porphyry intrusion. John Black, Chief Executive Officer of Aldebaran, commented as follows: "Drilling at Altar continues to grow the mineralized footprint of the deposit. With the drill holes reported today, we've extended known mineralization substantially to the north and south. To date, most of the reported drilling results from the 2023/2024 campaign have been from holes on the edges of the deposit where there was little to no drilling completed historically. While these holes may not be the most exciting from a grade perspective, they provide valuable information and are necessary to complete a resource update later this year. Moving forward, most of the remaining holes will focus on the core of the deposit, with a particular focus on growing Altar United and Altar East."

07:22 EDT Aya Gold & Silver sees 2024 production between 2.6M-3.2M silver oz. - 2024 guidance of between 2.6 and 3.2 million oz production at cash cost of between $13.00 and $14.50/oz. 2024 exploration budget of $36 million, prioritizing Boumadine, Zgounder, and Zgounder Regional.

07:19 EDT Purple Biotech to present data on NT219 at AACR 2024 - Purple Biotech announced it will present data for its oncology candidate NT219, a first-in-class small molecule, dual-inhibitor of IRS 1/2 and STAT3, in two poster presentations at the American Association for Cancer Research, AACR, annual meeting which takes place April 5-11, 2024, in San Diego, California. "The growing body of clinical, biomarker, and preclinical data for NT219 demonstrate its potential not only in the lead indication of recurrent/metastatic squamous cell carcinoma of the head and neck, but also in other solid-tumor cancers. These publications at AACR 2024 are a result of the progress made last year both in clinical and preclinical work bringing out NT219's attributes," stated Gil Efron, Chief Executive Officer of Purple Biotech. "We look forward to leveraging these data as we move forward with the clinical evaluation of NT219."

07:16 EDT FinWise Bancorp appoints Noone as President, Wahlman as CFO - FinWise Bancorp announced the appointment of Jim Noone to President along with the hiring and appointment of Robert Wahlman as Chief Financial Officer, CFO, effective immediately. Wahlman will succeed Javvis Jacobson, who will remain with the Bank as Treasurer. Noone, currently President of FinWise Bank, has been appointed by the Board of Directors to the position of President of FinWise Bancorp.Wahlman joins FinWise with over 35 years of total experience in the banking industry, including nearly 20 years as Chief Financial Officer of both private and publicly listed bank holding companies. Most recently, Wahlman served as the Chief Financial Officer of Axiom Bank and Axiom Bancshares.

07:15 EDT Gilat Satellite awarded $5M order from U.S. Department of Defense - Gilat Satellite Networks announced that the US Department of Defense awarded another $5 million order to one of the company's US-based subsidiaries, DataPath. This additional order is for DKET 3421 terminals, transportable satcom hubs that deliver the operational flexibility, capacity, connectivity, and control required to ensure success anywhere in the world. "We are pleased to receive yet another order for our revolutionary DKET 3421 from our valued military/government customer. This new order underscores the trust and confidence placed in the company and our capability to deliver mission-critical solutions that meet our customer's stringent requirements," said Barry W. Botts, Vice President, Sales and Business Development for DataPath. "This order further demonstrates our ability to provide reliable, easily transportable, and high-performance network hubs to meet the growing needs of our customers."

07:14 EDT Milestone Pharmaceuticals announces resubmission of NDA for etripamil - Milestone Pharmaceuticals announced the resubmission of its New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for etripamil, the Company's lead investigational product for the management of paroxysmal supraventricular tachycardia, PSVT. "We appreciate FDA's guidance through the resubmission process. We believe we have addressed all the issues raised in the Refusal to File letter and look forward to working with the Agency as it reviews our application," said Joseph Oliveto, President, and Chief Executive Officer of Milestone Pharmaceuticals. "If approved, we believe that etripamil nasal spray will be a valuable treatment option for patients suffering from PSVT."

07:11 EDT Arko Corp. negotiates improved payment terms, value for assets of TEG - ARKO announced that it has negotiated improved deferred payment terms and value related to the Company's previously reported acquisition of the assets of Transit Energy Group and its affiliates, TEG. As previously disclosed, on March 1, 2023, the Company closed on the acquisition from TEG of 135 convenience stores and gas stations, contracts to supply fuel to 181 dealer locations, and certain other assets. The purchase agreement originally provided for a total purchase price of approximately $370 million plus the value of inventory, of which $50 million was deferred and payable in two annual payments of $25 million on the first and second anniversaries of the closing, which ARKO could elect to pay in either cash or, subject to certain conditions, shares of ARKO's common stock. Pursuant to the original asset purchase agreement, on March 1, 2024, ARKO issued 3,417,915 shares of ARKO common stock to TEG at a price per share of $7.31 which was based on a 10-day volume weighted average price calculation outlined in the purchase agreement. The closing price of ARKO's common stock on the date ARKO notified TEG of its election to pay the first $25.0 million installment in shares was $8.36 per share, and the closing price on the date prior to the date of issuance was $6.53 per share. Subsequently, on March 26, 2024, ARKO entered into an amendment to the original purchase agreement with TEG, providing for ARKO's repurchase of the First Installment Shares at $5.66 per share, a 22.6% discount to the price at which the shares were issued, for a payment of approximately $19.3 million. ARKO and TEG also agreed to settle the second $25 million installment payment (which would have been due on March 1, 2025) for approximately $17.2 million in cash.

07:10 EDT Xilio to get $43.5M upfront in pact with Gilead to develop/commercialize XTX301 - Gilead Sciences (GILD) and Xilio Therapeutics(XLO) announced an exclusive license agreement to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies. The company is using its proprietary tumor-activation platform to build a pipeline of novel, tumor-activated molecules, including antibodies, cytokines, bispecifics, and cell engagers, which are designed to optimize the therapeutic index and localize anti-tumor activity within the tumor microenvironment. XTX301 is currently being evaluated in a Phase 1 dose escalation trial in patients with advanced solid tumors. Under the terms of the agreement, Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12. Xilio will receive $43.5M in upfront payments, including a cash payment of $30M and an initial equity investment by Gilead of $13.5M in Xilio common stock at a premium. Xilio will be eligible to receive up to $604 M in additional contingent payments, including additional equity investments by Gilead, a transition fee and specified development, regulatory and sales-based milestones. Xilio will also be eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales. Xilio will be responsible for conducting clinical development of XTX301 in the ongoing Phase 1 clinical trial through dose expansion. Following the delivery by Xilio of a specified clinical data package for XTX301, Gilead can elect to transition responsibilities for the development and commercialization of XTX301 to Gilead, subject to the terms of the agreement and payment by Gilead of a $75M transition fee. Prior to the potential transition fee, Xilio is eligible to receive up to a total of $29M in additional equity investments and a development milestone payment. Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction is expected to reduce Gilead's GAAP and non-GAAP 2024 EPS by approximately 3c - 4c.

07:09 EDT Regenxbio's ABBV-RGX-314 featured in published study for wet AMD - Regenxbio announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration - wet AMD -. These positive study results informed the ongoing pivotal trials of ABBV-RGX-314, a potential one-time gene therapy, for the treatment of wet AMD. The findings in The Lancet demonstrated that a single administration of ABBV-RGX-314 was generally well tolerated. Stable or improved visual acuity and retinal thickness was observed with few or no supplemental anti-VEGF injections in most patients at two years. Patients who received therapeutic doses demonstrated sustained levels of ABBV-RGX-314 protein and stable or improved vision and retinal anatomy with few, to no, supplemental anti-VEGF injections in most participants up to two years. ABBV-RGX-314 is currently being evaluated in patients with wet AMD in two pivotal trials. Enrollment is on track and these trials are expected to support global regulatory submissions with the FDA and the EMA in late 2025 through the first half of 2026.

07:06 EDT Sellas Life Sciences-licensed GFH009 included in trial combination for lymphoma - Sellas Life Sciences license partner GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland to start a combination study of GFH009 and Brukinsa in a multicenter phase Ib/II trial treating diffuse large B cell lymphoma. In 2022, GenFleet and Sellas Life Sciences entered into an exclusive license agreement across all therapeutic and diagnostic uses worldwide outside of Greater China. The first patient was dosed in the trial. GenFleet will conduct an open-label, single-arm and multi-center study in China of the combination therapy to evaluate the safety and efficacy among relapsed/refractory DLBCL patients. Around 100,000 patients are newly diagnosed non-Hodgkin's lymphoma per year in China, with DLBCL patients accounting for 40-50% of new cases. The trials of GFH009 treating peripheral T-cell lymphoma and acute myeloid leukemia have entered into phase II stage in China and the U.S. respectively. Numerous patients achieved complete or partial response. Preclinical research demonstrated GFH009's anti-proliferation effects on various tumor cell lines. GFH009 has been granted with both fast track and orphan drug designation from the FDA for the treatment of adult patients with relapsed/refractory peripheral T-cell lymphomas and r/r AML.

07:05 EDT Invivyd sees cash runway into 4Q24 - Cash and cash equivalents were $200.6 million as of December 31, 2023. Based on current operating plans and excluding anticipated cash collections from PEMGARDA sales, Invivyd expects its existing total cash and cash equivalents will enable the company to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2024.

07:02 EDT Iterum Therapeutics sees cash runway into 2025 - Subsequent to December 31, 2023, through February 29, 2024, Iterum sold 2.9 million ordinary shares under an at-the-market offering agreement, at an average price of $2.52 per share for net proceeds of $7.1 million, which has extended cash runway into 2025 based on its current operating plan. As of February 29, 2024, Iterum had approximately 16.4 million ordinary shares outstanding.

06:48 EDT iClick Interactive CFO David Zhang steps down, Josephine Ngai Yuk Chun succeeds - iClick Interactive Asia announced the appointment of Josephine Ngai Yuk Chun as CFO of the company, effective March 31. Ngai is currently a VP, finance and group financial controller of the company, and has been with iClick since 2019. She brings over 20 years of experience in financial accounting, financial management, and business operations to her new position. Ngai succeeds David Zhang who will step down from his roles as CFO and director of the company both effective March 31. Zhang will continue to work closely with iClick as a senior advisor.

06:32 EDT Tritium confirms effective date of reverse stock split - Tritium confirmed the effective date of its reverse stock split to consolidate company ordinary shares on the basis that every 200 shares be consolidated into one share. The effective date of the consolidation will be April 2.

06:17 EDT Autoliv retires 1.37M shares of repurchased stock - Autoliv announced that as of March 28, 2024, the total number of issued shares of common stock is 86,126,221 of which 81,373,679 shares are outstanding. Autoliv retired 1,370,057 shares of common stock that had been repurchased during the quarter which resulted in a decrease in the issued shares. The Company now has a total of 86,126,221 issued shares of common stock of which 81,373,679 shares are outstanding. Each share of outstanding common stock is entitled to one vote. After the retirement of the repurchased shares, Autoliv holds 4,752,542 shares of common stock in treasury which have no voting rights or rights to participate in distributions under Delaware law.

06:11 EDT Discover announces resignation of Michael Rhodes as CEO and president - In a regulatory filing on Wednesday, Discover (DFS) announced that its board accepted the resignation of Michael G. Rhodes from his positions as CEO and President of the company, a member of the board and a director and officer of Discover Bank, each effective April 1. Rhodes, who was not expected to have a long-term role at the combined company after completion of the company's merger with Capital One (COF), informed the board that he has accepted a job offer at another financial institution. Also on Wednesday, Ally Financial (ALLY) announced that Rhodes will be its new CEO, starting at the company on April 29.

06:06 EDT Twitch's top streamer, Ninja, reveals skin cancer diagnosis - Ninja, who has over 18.8 million followers on Twitch, said via X this week: "Alright I'm still in a bit of shock but want to keep you all updated. A few weeks ago I went in to a dermatologist for an annual skin/mole check that Jess proactively scheduled for me. There was a mole on the bottom of my foot that they wanted to remove just to be careful. It came back as melanoma, but they are optimistic that we caught it in the early stages. I had another dark spot appear near it, so today they biopsied that and removed a larger area around the melanoma with the hopes that under the microscope they will see clear non-melanoma edges and we will know we got it. I'm grateful to have hope in finding this early, but please take this as a PSA to get skin checkups." Reference Link

06:04 EDT Home Depot to acquire SRS Distribution for $18.25B, sees accretion - Home Depot has entered into a definitive agreement to acquire SRS Distribution, a residential specialty trade distribution company across several verticals serving the professional roofer, landscaper and pool contractor. SRS's 2,500-plus professional sales force and 760-plus branch network across 47 states, together with its 4,000-plus truck fleet and jobsite delivery capabilities, will enable The Home Depot to extend its offering to residential specialty trade pros while better serving renovator/remodelers. Tinker, as well as his senior leadership team, will continue to lead SRS. Tinker and team will work closely with Home Depot. Under the terms of the merger agreement, a subsidiary of The Home Depot will acquire SRS for a total enterprise value of approximately $18.25B. The closing of the acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to be completed by the end of fiscal 2024. The transaction is expected to be funded through cash on hand and debt. This transaction is expected to be dilutive to earnings-per-share from a GAAP perspective due to amortization expense, but accretive from a cash EPS perspective in the first year, post-closing, excluding synergies. The company intends to maintain its current credit ratings.

05:26 EDT Take-Two to acquire Gearbox Entertainment for $460M - Take-Two announced that it has entered into a definitive agreement with Embracer Group to acquire The Gearbox Entertainment Company, a creator of entertainment experiences, for $460M. The consideration consists entirely of newly issued shares of Take-Two common stock. The number of Take-Two shares will be calculated by dividing the purchase price by the average closing price per share on Nasdaq during the five trading day period ending on the trading day immediately prior to the closing date. The purchase price assumes a debt-free, cash-free company with a normalized level of net working capital at the time of the closing of the acquisition. The acquisition is anticipated to be completed during the first quarter of Take-Two's FY25, and is subject to the satisfaction of customary closing conditions, including applicable regulatory approvals. The transaction excludes certain third-party publishing and other assets that Take-Two deemed non-core to its business. Take-Two will acquire Gearbox's portfolio of intellectual property, including full ownership of "Borderlands" and "Tiny Tina's Wonderlands" franchises, as well as "Homeworld", "Risk of Rain", "Brothers in Arms", "Duke Nukem", and Gearbox's future pipeline. Gearbox currently has six interactive entertainment projects in various stages of development, including five sequels, two of which are from the Borderlands and Homeworld franchises, and at least one new intellectual property. Beyond these plans, Take-Two believes that there are incremental opportunities to invest in new projects and to expand Gearbox's proven franchises. Gearbox will operate as a studio within 2K and will be led by Founder and CEO, Randy Pitchford, and his management team. The acquisition adds a robust and proven development team to 2K's incredibly talented developer community, including personnel that have worked together on multiple critically and commercially successful games. Gearbox operates studios in Frisco, Texas; Montreal, Canada; and Quebec City, Canada.

05:14 EDT Sportradar, Oddin.gg enter multi-year strategic partnership - Sportradar and Oddin.gg announced they have entered into a multi-year strategic partnership to offer audiovisual streaming of Oddin's exclusive Esports content to Sportradar's betting operator clients around the world. The deal will support Oddin.gg's growth ambitions in the expanding global Esports market, whose betting turnover was estimated to be EUR 83B in 2023. It will extend the reach of Oddin.gg's official competition content by leveraging Sportradar's market leading position as an AV betting provider. Sportradar's global network of 900+ betting operator clients will benefit from the opportunity to offer greater volume and a wider variety of live streamed Esports events to their customers, increasing opportunities for engagement with existing and new betting markets. The partnership also paves the way for future collaboration in other areas. Oddin.gg holds the official rights to high-profile competitions including the newly released Counter Strike 2 which Sportradar will distribute to sportsbooks through the company's integrated streaming product, providing access to prominent competitions globally and enabling operators to offer exciting new content to their customers.